Literature DB >> 23149889

Abiraterone and its place in the treatment of metastatic CRPC.

Oliver Sartor1, Sumanta K Pal.   

Abstract

An update of the COU-AA-301 study confirms a survival advantage with abiraterone–prednisone compared to prednisone in post-docetaxel patients with metastatic castration-resistant prostate cancer. We place these data in the context of earlier disease states and other novel agents and explore practical issues concerning the future use of abiraterone.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23149889     DOI： 10.1038/nrclinonc.2012.202

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


  7 in total

1.  Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.

Authors:  Karim Fizazi; Howard I Scher; Arturo Molina; Christopher J Logothetis; Kim N Chi; Robert J Jones; John N Staffurth; Scott North; Nicholas J Vogelzang; Fred Saad; Paul Mainwaring; Stephen Harland; Oscar B Goodman; Cora N Sternberg; Jin Hui Li; Thian Kheoh; Christopher M Haqq; Johann S de Bono
Journal:  Lancet Oncol       Date:  2012-09-18       Impact factor: 41.316

2.  Increased survival with enzalutamide in prostate cancer after chemotherapy.

Authors:  Howard I Scher; Karim Fizazi; Fred Saad; Mary-Ellen Taplin; Cora N Sternberg; Kurt Miller; Ronald de Wit; Peter Mulders; Kim N Chi; Neal D Shore; Andrew J Armstrong; Thomas W Flaig; Aude Fléchon; Paul Mainwaring; Mark Fleming; John D Hainsworth; Mohammad Hirmand; Bryan Selby; Lynn Seely; Johann S de Bono
Journal:  N Engl J Med       Date:  2012-08-15       Impact factor: 91.245

3.  Duration of androgen suppression in the treatment of prostate cancer.

Authors:  Michel Bolla; Theodorus M de Reijke; Geertjan Van Tienhoven; Alphonsus C M Van den Bergh; Jorg Oddens; Philip M P Poortmans; Eliahu Gez; Paul Kil; Atif Akdas; Guy Soete; Oleg Kariakine; Elsbietha M van der Steen-Banasik; Elena Musat; Marianne Piérart; Murielle E Mauer; Laurence Collette
Journal:  N Engl J Med       Date:  2009-06-11       Impact factor: 91.245

4.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

Authors:  Howard I Scher; Susan Halabi; Ian Tannock; Michael Morris; Cora N Sternberg; Michael A Carducci; Mario A Eisenberger; Celestia Higano; Glenn J Bubley; Robert Dreicer; Daniel Petrylak; Philip Kantoff; Ethan Basch; William Kevin Kelly; William D Figg; Eric J Small; Tomasz M Beer; George Wilding; Alison Martin; Maha Hussain
Journal:  J Clin Oncol       Date:  2008-03-01       Impact factor: 44.544

Review 5.  Management of docetaxel failures in metastatic castrate-resistant prostate cancer.

Authors:  Sumanta K Pal; Brian Lewis; Oliver Sartor
Journal:  Urol Clin North Am       Date:  2012-08-29       Impact factor: 2.241

6.  Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?

Authors:  J Mezynski; C Pezaro; D Bianchini; A Zivi; S Sandhu; E Thompson; J Hunt; E Sheridan; B Baikady; A Sarvadikar; G Maier; A H M Reid; A Mulick Cassidy; D Olmos; G Attard; J de Bono
Journal:  Ann Oncol       Date:  2012-07-05       Impact factor: 32.976

7.  Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.

Authors:  Gerhardt Attard; Alison H M Reid; Roger A'Hern; Christopher Parker; Nikhil Babu Oommen; Elizabeth Folkerd; Christina Messiou; L Rhoda Molife; Gal Maier; Emilda Thompson; David Olmos; Rajesh Sinha; Gloria Lee; Mitch Dowsett; Stan B Kaye; David Dearnaley; Thian Kheoh; Arturo Molina; Johann S de Bono
Journal:  J Clin Oncol       Date:  2009-05-26       Impact factor: 44.544
  7 in total
  6 in total

1.  Luteolin, ellagic acid and punicic acid are natural products that inhibit prostate cancer metastasis.

Authors:  Lei Wang; Wenfang Li; Muqing Lin; Monika Garcia; David Mulholland; Michael Lilly; Manuela Martins-Green
Journal:  Carcinogenesis       Date:  2014-07-14       Impact factor: 4.944

2.  Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer.

Authors:  Ziyang Yu; Sen Chen; Adam G Sowalsky; Olga S Voznesensky; Elahe A Mostaghel; Peter S Nelson; Changmeng Cai; Steven P Balk
Journal:  Clin Cancer Res       Date:  2014-01-21       Impact factor: 12.531

3.  UAP1 is overexpressed in prostate cancer and is protective against inhibitors of N-linked glycosylation.

Authors:  H M Itkonen; N Engedal; E Babaie; M Luhr; I J Guldvik; S Minner; J Hohloch; M C Tsourlakis; T Schlomm; I G Mills
Journal:  Oncogene       Date:  2014-09-22       Impact factor: 9.867

Review 4.  Pomegranate and its components as alternative treatment for prostate cancer.

Authors:  Lei Wang; Manuela Martins-Green
Journal:  Int J Mol Sci       Date:  2014-08-25       Impact factor: 5.923

5.  Involvement of Bax and Bcl-2 in Induction of Apoptosis by Essential Oils of Three Lebanese Salvia Species in Human Prostate Cancer Cells.

Authors:  Alessandra Russo; Venera Cardile; Adriana C E Graziano; Rosanna Avola; Maurizio Bruno; Daniela Rigano
Journal:  Int J Mol Sci       Date:  2018-01-19       Impact factor: 5.923

6.  Sprouty2 loss-induced IL6 drives castration-resistant prostate cancer through scavenger receptor B1.

Authors:  Rachana Patel; Janis Fleming; Ernest Mui; Carolyn Loveridge; Peter Repiscak; Arnaud Blomme; Victoria Harle; Mark Salji; Imran Ahmad; Katy Teo; Freddie C Hamdy; Ann Hedley; Niels van den Broek; Gillian Mackay; Joanne Edwards; Owen J Sansom; Hing Y Leung
Journal:  EMBO Mol Med       Date:  2018-04       Impact factor: 12.137
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.